OmniAb (OABI) Insider John Higgins Buys 40,000 Shares
Insider John Higgins bought 40,000 shares of OmniAb, Inc. on June 17, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
John Higgins bought 40,000 shares of OmniAb, Inc. ($OABI) on June 17, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $OABI is up 12.3% after 1 week, up 4.4% after 1 month and up 126.1% to date (from the $2.03 close on Jun 17, 2026).
OABI
OmniAb, Inc.
Key Points
- John Higgins purchased 40,000 shares of OmniAb, Inc. on June 17, 2026, at a price of $2.34 per share, totaling approximately $93,600.
- Other insiders also traded on the same day, including Steven Love and Steven Crouse, who sold 20,000 shares each.
- OmniAb, which specializes in biotechnology, has a market cap of about $665.9 million and a revenue of $38.5 million.
Get $OABI trade alerts by text
We text you when insiders, Congress or big funds trade $OABI. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated OmniAb, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at OmniAb, Inc.
On June 17, 2026, John Higgins bought 40,000 shares of OmniAb, Inc. (OABI) on the NasdaqGM at a price of $2.34 per share. This purchase is valued at approximately $93,600.
Other Insiders Active on the Same Day
On the same day, several other insiders also made trades. Steven Love and Philip Gotwals each sold 20,000 shares, while Steven Crouse sold 20,000 shares and also bought 20,000 shares. This flurry of trading indicates notable activity among the company's insiders.
How OmniAb, Inc. Stock Has Traded
At $2.34, OmniAb shares are trading significantly below their 52-week high of $5.43, which may present an opportunity for investors. The stock has recently fluctuated around its 50-day moving average of $3.38, suggesting some volatility in its price.
Analysts Set New Price Targets
Analysts have been maintaining a positive outlook on OmniAb. On October 7, 2026, Leerink Partners maintained an "Outperform" rating with a target price of $12.00, while StoneX also maintained a "Buy" rating with a target of $6.00. HC Wainwright & Co. reiterated a "Buy" rating with a target of $11.00 on August 17, 2026.
What OmniAb, Inc. Does
OmniAb, Inc. is a biotechnology firm that licenses technology for discovering therapeutics. The company’s innovative platform helps create and screen antibodies for drug development, serving clients worldwide in the pharmaceutical and biotech sectors.
What’s Next for OmniAb
Investors will be looking forward to the next earnings report scheduled for November 4, 2026. As a reminder, the recent trades reflect insider activity as of June 17, 2026, and do not necessarily indicate current positions.
Related Filing Alerts
Source: John Higgins's Form 4 filing on $OABI (Jun 17, 2026). Find the original filing: OABI Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts